We studied patients who had been
hospitalized for an acute coronary syndrome and
enrolled them immediately after their condition had
stabilized. Three quarters of the patients were treated
with an early invasive strategy, and the majority
were treated with multiple medications for secondary
prevention, including antiplatelet therapy, betablockers,
and angiotensin-converting–enzyme inhibitors
(and a statin as part of the trial design).